Drugs by Condition

Multiple Myeloma Medications

Definition of Multiple Myeloma: Multiple myeloma is a cancer of the plasma cells in bone marrow.

Drugs associated with Multiple Myeloma

The following drugs and medications are in some way related to, or used in the treatment of Multiple Myeloma. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

See sub-conditions

Drug Name ( View by: Brand \| Generic )	Reviews	Ratings
Revlimid (More...) generic name: lenalidomide class: miscellaneous antineoplastics	0 review(s)	Not rated - Be the first
Cytoxan (Pro, More...) generic name: cyclophosphamide class: alkylating agents	0 review(s)	Not rated - Be the first
Adriamycin (More...) generic name: doxorubicin class: antibiotics/antineoplastics	0 review(s)	Not rated - Be the first
Velcade (Pro, More...) generic name: bortezomib class: miscellaneous antineoplastics	1 review(s)	Not rated - Be the first
Thalomid (More...) generic name: thalidomide class: leprostatics, miscellaneous antineoplastics	0 review(s)	Not rated - Be the first
Doxil (More...) generic name: doxorubicin liposomal class: antibiotics/antineoplastics	0 review(s)	Not rated - Be the first
Alkeran (Pro, More...) generic name: melphalan class: alkylating agents	0 review(s)	Rate It!	4.0
Oncovin (More...) generic name: vincristine class: mitotic inhibitors	0 review(s)	Not rated - Be the first
Gliadel (More...) generic name: carmustine class: alkylating agents	0 review(s)	Not rated - Be the first
BiCNU (Pro, More...) generic name: carmustine class: alkylating agents	0 review(s)	Not rated - Be the first
Vincasar PFS (More...) generic name: vincristine class: mitotic inhibitors	0 review(s)	Not rated - Be the first
Cytoxan Lyophilized (More...) generic name: cyclophosphamide class: alkylating agents	0 review(s)	Not rated - Be the first
Neosar (More...) generic name: cyclophosphamide class: alkylating agents	0 review(s)	Not rated - Be the first

Latest Multiple Myeloma Blog Post

CytRx's Tamibarotene Demonstrates Statistically Significant Anti-Tumor Activity in Animal Trial for Multiple Myeloma
Data Broadens Tamibarotene's Potential Therapeutic Indications beyond APL LOS ANGELES--(BUSINESS WIRE)--Jun 17, 2009 - CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company engaged in the development of high-value human...

View all Multiple Myeloma blog posts.